Skip to main content
Erschienen in: Diabetologia 4/2017

08.12.2016 | Article

Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels

verfasst von: Joshua R. Willard, Breanne M. Barrow, Sakeneh Zraika

Erschienen in: Diabetologia | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Aim/hypothesis

Neprilysin, a widely expressed peptidase, is upregulated in metabolically altered states such as obesity and type 2 diabetes. Like dipeptidyl peptidase-4 (DPP-4), neprilysin can degrade and inactivate the insulinotropic peptide glucagon-like peptide-1 (GLP-1). Thus, we investigated whether neprilysin deficiency enhances active GLP-1 levels and improves glycaemia in a mouse model of high fat feeding.

Methods

Nep +/+ and Nep −/− mice were fed a 60% fat diet for 16 weeks, after which active GLP-1 and DPP-4 activity levels were measured, as were glucose, insulin and C-peptide levels during an OGTT. Insulin sensitivity was assessed using an insulin tolerance test.

Results

High-fat-fed Nep −/− mice exhibited elevated active GLP-1 levels (5.8 ± 1.1 vs 3.5 ± 0.8 pmol/l, p < 0.05) in association with improved glucose tolerance, insulin sensitivity and beta cell function compared with high-fat-fed Nep +/+ mice. In addition, plasma DPP-4 activity was lower in high-fat-fed Nep −/− mice (7.4 ± 1.0 vs 10.7 ± 1.3 nmol ml−1 min−1, p < 0.05). No difference in insulin:C-peptide ratio was observed between Nep −/− and Nep +/+ mice, suggesting that improved glycaemia does not result from changes in insulin clearance.

Conclusions/interpretation

Under conditions of increased dietary fat, an improved glycaemic status in neprilysin-deficient mice is associated with elevated active GLP-1 levels, reduced plasma DPP-4 activity and improved beta cell function. Thus, neprilysin inhibition may be a novel treatment strategy for type 2 diabetes.
Literatur
1.
Zurück zum Zitat Muangman P, Spenny ML, Tamura RN, Gibran NS (2003) Fatty acids and glucose increase neutral endopeptidase activity in human microvascular endothelial cells. Shock 19:508–512CrossRefPubMed Muangman P, Spenny ML, Tamura RN, Gibran NS (2003) Fatty acids and glucose increase neutral endopeptidase activity in human microvascular endothelial cells. Shock 19:508–512CrossRefPubMed
2.
Zurück zum Zitat Antezana M, Sullivan S, Usui M et al (2002) Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers. J Invest Dermatol 119:1400–1404CrossRefPubMed Antezana M, Sullivan S, Usui M et al (2002) Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers. J Invest Dermatol 119:1400–1404CrossRefPubMed
3.
Zurück zum Zitat Standeven KF, Hess K, Carter AM et al (2011) Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond) 35:1031–1040CrossRef Standeven KF, Hess K, Carter AM et al (2011) Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond) 35:1031–1040CrossRef
4.
Zurück zum Zitat Zraika S, Koh DS, Barrow BM, Lu B, Kahn SE, Andrikopoulos S (2013) Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx. Diabetes 62:1593–1601CrossRefPubMedPubMedCentral Zraika S, Koh DS, Barrow BM, Lu B, Kahn SE, Andrikopoulos S (2013) Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx. Diabetes 62:1593–1601CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Arbin V, Claperon N, Fournie-Zaluski MC, Roques BP, Peyroux J (2001) Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br J Pharmacol 133:495–502CrossRefPubMedPubMedCentral Arbin V, Claperon N, Fournie-Zaluski MC, Roques BP, Peyroux J (2001) Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br J Pharmacol 133:495–502CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Arbin V, Claperon N, Fournie-Zaluski MC, Roques BP, Peyroux J (2003) Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats. J Cardiovasc Pharmacol 41:254–264CrossRefPubMed Arbin V, Claperon N, Fournie-Zaluski MC, Roques BP, Peyroux J (2003) Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats. J Cardiovasc Pharmacol 41:254–264CrossRefPubMed
7.
Zurück zum Zitat Wang CH, Leung N, Lapointe N et al (2003) Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation 107:1923–1929CrossRefPubMed Wang CH, Leung N, Lapointe N et al (2003) Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation 107:1923–1929CrossRefPubMed
8.
Zurück zum Zitat Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O (1994) Structure-activity studies of glucagon-like peptide-1. J Biol Chem 269:6275–6278PubMed Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O (1994) Structure-activity studies of glucagon-like peptide-1. J Biol Chem 269:6275–6278PubMed
9.
Zurück zum Zitat Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829–835CrossRefPubMed Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829–835CrossRefPubMed
10.
Zurück zum Zitat Hupe-Sodmann K, Goke R, Goke B et al (1997) Endoproteolysis of glucagon-like peptide (GLP)-1 (7–36) amide by ectopeptidases in RINm5F cells. Peptides 18:625–632CrossRefPubMed Hupe-Sodmann K, Goke R, Goke B et al (1997) Endoproteolysis of glucagon-like peptide (GLP)-1 (7–36) amide by ectopeptidases in RINm5F cells. Peptides 18:625–632CrossRefPubMed
11.
Zurück zum Zitat Hupe-Sodmann K, McGregor GP, Bridenbaugh R et al (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149–156CrossRefPubMed Hupe-Sodmann K, McGregor GP, Bridenbaugh R et al (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149–156CrossRefPubMed
12.
Zurück zum Zitat Plamboeck A, Holst JJ, Carr RD, Deacon CF (2005) Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48:1882–1890CrossRefPubMed Plamboeck A, Holst JJ, Carr RD, Deacon CF (2005) Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48:1882–1890CrossRefPubMed
13.
Zurück zum Zitat Lu B, Gerard NP, Kolakowski LF Jr et al (1995) Neutral endopeptidase modulation of septic shock. J Exp Med 181:2271–2275CrossRefPubMed Lu B, Gerard NP, Kolakowski LF Jr et al (1995) Neutral endopeptidase modulation of septic shock. J Exp Med 181:2271–2275CrossRefPubMed
14.
Zurück zum Zitat Terashima H, Okamoto A, Menozzi D, Goetzl EJ, Bunnett NW (1992) Identification of neuropeptide-degrading enzymes in the pancreas. Peptides 13:741–748CrossRefPubMed Terashima H, Okamoto A, Menozzi D, Goetzl EJ, Bunnett NW (1992) Identification of neuropeptide-degrading enzymes in the pancreas. Peptides 13:741–748CrossRefPubMed
15.
Zurück zum Zitat Matheeussen V, Lambeir AM, Jungraithmayr W et al (2012) Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta 413:456–462CrossRefPubMed Matheeussen V, Lambeir AM, Jungraithmayr W et al (2012) Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta 413:456–462CrossRefPubMed
16.
Zurück zum Zitat Ahmed RH, Huri HZ, Al-Hamodi Z, Salem SD, Muniandy S (2015) Serum levels of soluble CD26/Dipeptidyl Peptidase-IV in type 2 diabetes mellitus and its association with metabolic syndrome and therapy with antidiabetic agents in Malaysian subjects. PLoS One 10, e0140618CrossRefPubMedPubMedCentral Ahmed RH, Huri HZ, Al-Hamodi Z, Salem SD, Muniandy S (2015) Serum levels of soluble CD26/Dipeptidyl Peptidase-IV in type 2 diabetes mellitus and its association with metabolic syndrome and therapy with antidiabetic agents in Malaysian subjects. PLoS One 10, e0140618CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Lamers D, Famulla S, Wronkowitz N et al (2011) Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60:1917–1925CrossRefPubMedPubMedCentral Lamers D, Famulla S, Wronkowitz N et al (2011) Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60:1917–1925CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Bayes-Genis A, Barallat J, Richards AM (2016) A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol 68:639–653CrossRefPubMed Bayes-Genis A, Barallat J, Richards AM (2016) A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol 68:639–653CrossRefPubMed
19.
Zurück zum Zitat Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M (2001) Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 19:673–680PubMed Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M (2001) Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 19:673–680PubMed
20.
Zurück zum Zitat Bauvois B, Djavaheri-Mergny M, Rouillard D, Dumont J, Wietzerbin J (2000) Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells. Oncogene 19:265–272CrossRefPubMed Bauvois B, Djavaheri-Mergny M, Rouillard D, Dumont J, Wietzerbin J (2000) Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells. Oncogene 19:265–272CrossRefPubMed
21.
Zurück zum Zitat Wensveen FM, Jelencic V, Valentic S et al (2015) NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol 16:376–385CrossRefPubMed Wensveen FM, Jelencic V, Valentic S et al (2015) NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol 16:376–385CrossRefPubMed
22.
Zurück zum Zitat Simonsen L, Pilgaard S, Carr RD, Kanstrup AB, Holst JJ, Deacon CF (2009) Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto–Kakizaki rats. Horm Metab Res 41:851–853CrossRefPubMed Simonsen L, Pilgaard S, Carr RD, Kanstrup AB, Holst JJ, Deacon CF (2009) Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto–Kakizaki rats. Horm Metab Res 41:851–853CrossRefPubMed
23.
Zurück zum Zitat Akash MS, Rehman K, Chen S (2013) Goto–Kakizaki rats: its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus. Curr Diabetes Rev 9:387–396CrossRefPubMed Akash MS, Rehman K, Chen S (2013) Goto–Kakizaki rats: its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus. Curr Diabetes Rev 9:387–396CrossRefPubMed
24.
Zurück zum Zitat Davidson E, Coppey L, Lu B et al (2009) The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Exp Diabetes Res 2009:431980PubMed Davidson E, Coppey L, Lu B et al (2009) The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Exp Diabetes Res 2009:431980PubMed
25.
Zurück zum Zitat Coppey L, Lu B, Gerard C, Yorek MA (2012) Effect of inhibition of angiotensin-converting enzyme and/or neutral endopeptidase on neuropathy in high-fat-fed C57Bl/6J mice. J Obes 2012:326806CrossRefPubMedPubMedCentral Coppey L, Lu B, Gerard C, Yorek MA (2012) Effect of inhibition of angiotensin-converting enzyme and/or neutral endopeptidase on neuropathy in high-fat-fed C57Bl/6J mice. J Obes 2012:326806CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Davidson EP, Coppey LJ, Dake B, Yorek MA (2011) Effect of treatment of Sprague Dawley rats with AVE7688, enalapril, or candoxatril on diet-induced obesity. J Obes 2011:686952CrossRefPubMed Davidson EP, Coppey LJ, Dake B, Yorek MA (2011) Effect of treatment of Sprague Dawley rats with AVE7688, enalapril, or candoxatril on diet-induced obesity. J Obes 2011:686952CrossRefPubMed
27.
28.
Zurück zum Zitat McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMed McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMed
Metadaten
Titel
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels
verfasst von
Joshua R. Willard
Breanne M. Barrow
Sakeneh Zraika
Publikationsdatum
08.12.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 4/2017
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-4172-4

Weitere Artikel der Ausgabe 4/2017

Diabetologia 4/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.